Pharmacological targeting of Nrf2/ARE pathways has been proposed as a therapeutic strategy against neurodegenerative disorders, including ALS, since it helps neuronal cells to cope with OS [169]. The gene discussed is NFE2L2; the disease is amyotrophic lateral sclerosis.